Raymond Debbane
CIK: 0001053890
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LEXICON PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Jun 3, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Exercise(M)Direct89.3K shares- - May 1, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
35.7K shares- - May 1, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Award(A)DirectStock Option (Right to Buy)
43.5K shares- - Feb 25, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Purchase(P)Direct2K shares at avg. $1.49$3K - Feb 23, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Purchase(P)Direct100K shares at avg. $1.47$147K - Feb 20, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Purchase(P)Direct100K shares at avg. $1.48$148K - Feb 19, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Purchase(P)Direct50K shares at avg. $1.44$72K - Feb 18, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Purchase(P)Direct133.7K shares at avg. $1.32$176K - Feb 17, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Purchase(P)Direct76.9K shares at avg. $1.31$101K - Feb 13, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
Purchase(P)Direct58K shares at avg. $1.31$76K - Jun 3, 2025LXRX
LEXICON PHARMACEUTICALS, INC.
Award(A)DirectStock Option (Right to Buy)
103.8K shares- - Jun 3, 2025LXRX
LEXICON PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
89.3K shares- - May 13, 2025LXRX
LEXICON PHARMACEUTICALS, INC.
Exercise(M)Direct36.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 3, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Exercise(M) | 89,312 | - | $0 | Direct |
| May 1, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 35,714 | - | - | Direct |
| May 1, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Award(A) Stock Option (Right to Buy) | 43,478 | - | - | Direct |
| Feb 25, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Purchase(P) | 2,000 | $1.49 | $2,980 | Direct |
| Feb 23, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Purchase(P) | 100,000 | $1.47 | $147,000 | Direct |
| Feb 20, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Purchase(P) | 100,000 | $1.48 | $147,790 | Direct |
| Feb 19, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Purchase(P) | 50,000 | $1.44 | $71,965 | Direct |
| Feb 18, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Purchase(P) | 133,688 | $1.32 | $176,468 | Direct |
| Feb 17, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Purchase(P) | 76,857 | $1.31 | $100,544 | Direct |
| Feb 13, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Purchase(P) | 57,952 | $1.31 | $75,877 | Direct |
| Jun 3, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | Award(A) Stock Option (Right to Buy) | 103,806 | - | - | Direct |
| Jun 3, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 89,312 | - | - | Direct |
| May 13, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | Exercise(M) | 36,810 | - | - | Direct |
1-13 of 13 transactions
About DEBBANE RAYMOND
DEBBANE RAYMOND (SEC CIK 0001053890) files insider reports with the SEC as Director of LEXICON PHARMACEUTICALS, INC. (LXRX).
Signal8 holds 8 ownership filings by DEBBANE RAYMOND, all Form 4s, filed between May 13, 2025 and Jun 4, 2026. Those filings report 13 transactions, from May 13, 2025 to Jun 3, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on DEBBANE RAYMOND's filings is in THE WOODLANDS, TX.
Recent filings by DEBBANE RAYMOND
- Jun 3, 2026: Option exercise of LXRX shares (Form 4, code M).
- May 1, 2026: Grants or awards of LXRX derivative securities (2 lines, Form 4, code A).
- Feb 25, 2026: Open-market purchase of LXRX shares (Form 4, code P).
- Feb 23, 2026: Open-market purchase of LXRX shares (Form 4, code P).
- Feb 20, 2026: Open-market purchase of LXRX shares (Form 4, code P).
Other insiders filing for LEXICON PHARMACEUTICALS, INC. (LXRX)
- Swain Judith L, Director
- Sullivan Diane E., Director
- SOBECKI CHRISTOPHER J, Director
- Cheung Ivan, Director
- BARKER SAM L, Director
- Amouyal Philippe, Director